Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 244

Similar articles for PubMed (Select 23683069)

1.

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.

Hermansen K, Bækdal TA, Düring M, Pietraszek A, Mortensen LS, Jørgensen H, Flint A.

Diabetes Obes Metab. 2013 Nov;15(11):1040-8. doi: 10.1111/dom.12133. Epub 2013 Jun 11.

2.

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH.

Int J Obes (Lond). 2014 Jun;38(6):784-93. doi: 10.1038/ijo.2013.162. Epub 2013 Sep 3.

3.

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

Flint A, Kapitza C, Hindsberger C, Zdravkovic M.

Adv Ther. 2011 Mar;28(3):213-26. doi: 10.1007/s12325-010-0110-x. Epub 2011 Feb 17.

PMID:
21340616
4.

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.

PMID:
16816950
5.

Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.

Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T.

Diabetes Care. 2014 Jul;37(7):1797-805. doi: 10.2337/dc13-3007.

PMID:
24929431
6.

Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.

Voukali M, Kastrinelli I, Stragalinou S, Tasiopoulou D, Paraskevopoulou P, Katsilambros N, Kokkinos A, Tentolouris N, Ioannidis I.

J Diabetes Res. 2014;2014:304032. doi: 10.1155/2014/304032. Epub 2014 Aug 4.

7.

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.

Kapitza C, Zdravkovic M, Hindsberger C, Flint A.

Adv Ther. 2011 Aug;28(8):650-60. doi: 10.1007/s12325-011-0044-y. Epub 2011 Jul 20.

PMID:
21792552
8.

The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.

Flint A, Kapitza C, Zdravkovic M.

Diabetes Obes Metab. 2013 Oct;15(10):958-62. doi: 10.1111/dom.12108. Epub 2013 Apr 23.

PMID:
23551925
9.
10.

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD.

Atherosclerosis. 2010 Sep;212(1):217-22. doi: 10.1016/j.atherosclerosis.2010.05.028. Epub 2010 May 25.

PMID:
20557887
12.

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A.

Diabetes Obes Metab. 2013 Jul;15(7):642-9. doi: 10.1111/dom.12076. Epub 2013 Feb 25.

13.

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K.

Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.

PMID:
20199137
14.

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.

Diabetes Res Clin Pract. 2012 Aug;97(2):258-66. doi: 10.1016/j.diabres.2012.02.016. Epub 2012 Mar 24.

PMID:
22446097
15.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.

Curr Med Res Opin. 2008 Oct;24(10):2943-52. doi: 10.1185/03007990802418851 . Epub 2008 Sep 10.

PMID:
18786299
16.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2.

PMID:
21723606
17.

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.

PMID:
9730852
18.

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR, Smith U.

Diabetologia. 2012 Apr;55(4):915-25. doi: 10.1007/s00125-011-2447-3. Epub 2012 Jan 12.

PMID:
22237690
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk